ACELYRIN, Inc. has announced its confidence in a proposed merger with Alumis Inc., scheduled for a stockholder vote on May 13, 2025. The merger aims to create a leading clinical-stage immunology company with a diversified portfolio of product candidates. ACELYRIN's Board of Directors emphasizes that the merger represents the culmination of a comprehensive and competitive process designed to maximize value for all stockholders. ACELYRIN stockholders are expected to retain approximately 48% ownership in the combined company, providing them with significant potential upside. The Board encourages stockholders to focus on the long-term benefits of the merger.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.